MedTrace Logo

Fluorometholone Study

NCT07308938 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2026-04-09

No results posted yet for this study

Summary

The investigators seek to determine whether adjunctive topical fluorometholone (FML) improves best-corrected visual acuity (BCVA) at 3 months in patients with bacterial corneal ulcers compared with standard topical antibiotic therapy alone.

Conditions

  • Keratitis Bacterial
  • Corneal Ulcer (Diagnosis)

Interventions

DRUG

Adjunctive Topical Fluorometholone (FML) 0.1%

Adjunctive Topical Fluorometholone (FML) 0.1% will be used

DRUG

Standard Topical Antibiotic Therapy

Patients will be treated with antibiotics (Cefazolin, Tobramycin or Moxifloxacin) we per treating physician

Sponsors & Collaborators

  • University of Pittsburgh Medical Center

    collaborator OTHER

  • Vishal Jhanji

    lead OTHER

Principal Investigators

  • Vishal Jhanji, MD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2029-12-31
Completion
2030-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07308938 on ClinicalTrials.gov